Positive Outlook for Blueprint Medicines Driven by Strong Ayvakit Performance and Pipeline Progress

TD Cowen analyst Marc Frahm has maintained their bullish stance on BPMC stock, giving a Buy rating today.

Marc Frahm’s rating is based on several positive indicators for Blueprint Medicines. The company’s Q1 financial performance, particularly the Ayvakit revenue, met consensus expectations and alleviated investor concerns about potential shortfalls. This was supported by a strong demand growth in the U.S., where the penetration of Ayvakit among diagnosed ISM patients remains low, indicating significant room for future expansion.
Additionally, the management’s decision to increase full-year revenue guidance reflects confidence in sustained demand and improving market conditions. Despite some variability in ex-U.S. sales, the expectation of continued growth and new reimbursement agreements further supports the optimistic outlook. Moreover, the progress in the development of BLU-808, a key pipeline asset, adds to the potential for future growth, with early data expected by year-end. These factors collectively underpin Marc Frahm’s Buy rating for Blueprint Medicines.

According to TipRanks, Frahm is an analyst with an average return of -0.8% and a 32.16% success rate. Frahm covers the Healthcare sector, focusing on stocks such as Incyte, Blueprint Medicines, and Scholar Rock Holding.

In another report released today, Needham also maintained a Buy rating on the stock with a $130.00 price target.